On May 28, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of its Interim Report for the period January – March 2021 (Press release, Allarity Therapeutics, MAY 28, 2021, View Source [SID1234583273]). The report is available as an attached document and on the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve Carchedi, CEO of Allarity Therapeutics, stated, "2021 has already been a year full of significant events for Allarity. We have initiated our IXEMPRA Phase 2 trial in Europe, and we made progress on multiple fronts in our effort to achieve U.S. marketing approval for dovitinib together with its DRP companion diagnostic, and we remain committed to filing the New Drug Application (NDA) for dovitinib later this year with the U.S. FDA. Moreover, we expanded our preclinical testing of stenoparib’s antiviral properties to include both the British and South African variant of Coronavirus. On the financial side, we have ceased to rely on convertible notes as our main source of funding. Instead, we have announced two new financing events, one a rights issue and one a U.S. $20M investment, the largest in our Company’s history, which is conditional on our company transforming into a U.S. company and listing on the U.S. Nasdaq Stock Market. I look forward to our achievement of further strategic milestones during the remainder of this year."

Summary of the Interim Report

Consolidated group revenue amounted to 0 MDKK (0 MDKK).
Consolidated group loss before depreciation amounted to -15.8 MDKK (-17.3 MDKK).
Consolidated group loss before net financials amounted to -16.0 MDKK (-17.6 MDKK).
Consolidated net result amounted to -17.6 MDKK (-15.4 MDKK).
Consolidated earnings per share (EPS) amounted to -0.08 DKK (-0.12 DKK).

2020 numbers in brackets.

Highlights during Q1 2021

January

On January 26, Allarity Therapeutics announced that it would test its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus in preclinical studies.

February

On February 11, the Company announced that it had drawn down a fourth tranche under its convertible note agreement with Negma Group LTD and Park Partners GP.
On February 24, the Company provided an update on the pre-clinical testing of stenoparib’s antiviral activity against new variants of Coronavirus.
March

On March 3, the Company published that it had initiated a Phase 2 trial of IXEMPRA in Europe for the treatment of metastatic breast cancer.
On March 9, the Company announced positive data from a preclinical study of dovitinib in osteosarcoma.
On March 23, the Company announced plans of fully guaranteed rights issue of approximately SEK 100 million.
On March 31, the Company published its annual report for 2020.
On March 31, the Company published a notice to convene the Annual General Meeting to be held on Thursday 15 April 2021 at 15:00 (CEST).

Highlights after the period

April

On April 2, the Company submitted a PreMarket Approval (PMA) application to the U.S. FDA for the DRP companion diagnostic for dovitinib.
On April 15, the Company published the minutes of the Annual General Meeting 2021.
On April 29, the Company announced that a Dovitinib-DRP e-Poster will be presented at the European Association for Cancer Research (EACR) 2021 Virtual Congress to be held from 9-12 June 2021.

May

On May 19, the Company announced that it would conduct a Rights Issue of new shares, and it had published a prospectus regarding the Rights Issue.
On May 21, the Company announced that it had secured an investment from 3i Fund for recapitalization, transition to listing on U.S. Nasdaq, and advancing the company’s pipeline of priority oncology therapeutics.
The report is available on: View Source

Online webcast/conference call

Allarity Therapeutics will host a live webcast on 28 May 2021, at 5:00 p.m. CEST to discuss the company’s first-quarter 2021 results and provide a business and financial update.

Attendees are encouraged to pre-register in order to be able to watch the presentation slides using this link: View Source